Logo for Xilio Therapeutics Inc

Xilio Therapeutics Investor Relations Material

Latest events

Logo for Xilio Therapeutics Inc

Study Update

Xilio Therapeutics
Logo for Xilio Therapeutics

Q1 2025

16 May, 2025
Logo for Xilio Therapeutics

Q4 2024

11 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies

Latest reports from Xilio Therapeutics Inc

Access all reports
Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm focusing on discovering and developing tumor-activated immuno-oncology therapies. It focuses on creating treatments that are activated in the tumor environment, aiming to enhance the efficacy of immuno-oncology treatments while minimizing side effects. The company's portfolio includes a checkpoint inhibitor program with XTX101, an anti-CTLA-4 monoclonal antibody, alongside cytokine programs featuring XTX202 (a tumor-activated IL-2) and XTX301 (an engineered IL-12 molecule). The company is headquartered in Waltham, Massachusetts, and its shares are listed on the NASDAQ.